Resolute Capital Asset Partners’s Legend Biotech LEGN Stock Holding History

Resolute Capital Asset Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.53M	Buy	+260,871	New	+$7.04M	3.22%	7
2025 Q4	–	Sell	-30,963	Closed	-$1.01M	–	60
2025 Q3	$1.01M	Sell	30,963 -20,000	-39%	-$738K	0.53%	42
2025 Q2	$1.81M	Sell	50,963 -9,037	-15%	-$293K	0.95%	35
2025 Q1	$2.04M	Buy	+60,000	New	+$2.15M	1.15%	30
2024 Q4	–	Sell	-60,000	Closed	-$2.92M	–	40
2024 Q3	$2.92M	Buy	+60,000	New	+$3.2M	1.52%	25

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Resolute Capital Asset Partners's LEGN Position: Q2 2026 in Review

Resolute Capital Asset Partners opened a new position in Legend Biotech (LEGN) in Q2 2026: 260,871 shares worth $7.53M. The stake represents 3.22% of the portfolio and ranks #7 among its holdings. This is a return to the name: Resolute Capital Asset Partners previously reported a position in LEGN as recently as Q3 2025.

Resolute Capital Asset Partners first reported a position in LEGN in Q3 2024 and has held it in 5 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Resolute Capital Asset Partners held 260,871 shares of Legend Biotech worth $7.53M as of Q2 2026.
Legend Biotech was a new Resolute Capital Asset Partners position in Q2 2026.
Legend Biotech made up 3.22% of Resolute Capital Asset Partners's portfolio in Q2 2026, its #7 holding.
Resolute Capital Asset Partners first reported a position in Legend Biotech in Q3 2024 and has held it in 5 quarters since.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q2 2026, filed 14 Aug 2026.